Skip to main content

Table 2 Activities of sansanmycin analogues

From: Improving the N-terminal diversity of sansanmycin through mutasynthesis

Compounds

(sansanmycin)

MIC (μg/ml)

E. coli ΔtolC

P. aeruginosa 11

B. subtilis CMCC (B) 63501

M. tuberculosis

H37Rv

FJ05189

FJ05120

FJ05195

MX-1

32

>128

>128

16

8

8

8

MX-2

2

32

>128

16

16

8

8

MX-3

>128

>128

64

    

MX-4

8

64

>128

8

16

8

16

MX-5

8

>128

>128

    

MX-6

4

32

16

8

8

8

8

MX-7

8

128

>128

16

8

8

16

MX-8

8

128

>128

    

MX-9

16

128

>128

    

MX-10

64

>128

>128

    

A

2

16

>128

16

16

16

8

Streptomycin

16

4

2

0.25

<0.06

<0.06

>128

Isoniazid

   

0.125

8

16

>128

Rifampicin

   

<0.06

4

>128

>128

Ethambutol

   

0.5

2

0.5

>128

  1. M. tuberculosis H37Rv, standard and susceptible strain. FJ05189, FJ05120 and FJ05195 are clinical isolates of M. tuberculosis. FJ05189 and FJ05120, MDR strains, resistant to isoniazid and rifampicin; FJ05195, XDR strain, resistant to isoniazid, rifampicin, ethambutol, streptomycin, kanamycin and ofloxacin
Back to article page

Microbial Cell Factories

ISSN: 1475-2859

Contact us